Page 192 - 2019秋季手冊內頁-ebook測試

衛生福利部雙和醫院(委託臺北醫學大學興建經營)
5
Sitravatinib in the Tumor Microenvironment (TME)
衛生福利部雙和醫院(委託臺北醫學大學興建經營)
6
Sitravatinib Inhibits Immunosuppressive Immune Populations and Augments
Checkpoint Inhibitor Therapy
Inhibition of M2 macrophage polarization by Sitravatinib decreases M2 MΦs, M-MDSCs and increases CD4 Sitravatinib augments PD-1 therapy in CPI sitra or MERTK KO ex vivo and CD8 cells in a syngeneic model refractory models
Du W, et al, Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight, 2018
• Sitravatinib shifts macrophage polarization M2 M1, depletes • Sitravatinib augments PD-1 therapy in CPI-refractory models and in mice with MDSCs and increases CD8+ T cells in tumor-bearing syngeneic mice complete responses to sitravatinib + PD-1 therapy, tumors do not form upon re-
innoculation, confirming an adaptive immunity-based mechanism
193
Spleen Tumor
LYMPHOCYTE LYMPHOCYTE MYELOID